A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
Clinical trial NCT07593820 · RECRUITING
Trial details
- NCT number
- NCT07593820
- Sponsor
- Vall d'Hebron Institute of Oncology
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-29
- Primary completion
- 2030-06-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.